Grifols S.A. (MC:GRF) — Market Cap & Net Worth
Market Cap & Net Worth: Grifols S.A. (GRF)
Grifols S.A. (MC:GRF) has a market capitalization of $4.76 Billion (€4.07 Billion) as of April 19, 2026. Listed on the MC stock exchange, this Spain-based company holds position #3598 globally and #27 in its home market, demonstrating a 8.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Grifols S.A.'s stock price €9.65 by its total outstanding shares 422285368 (422.29 Million).
Grifols S.A. Market Cap History: 2015 to 2026
Grifols S.A.'s market capitalization history from 2015 to 2026. Data shows change from $9.86 Billion to $4.76 Billion (-6.08% CAGR).
Index Memberships
Grifols S.A. is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
IBEX 35 Index
IBEX
|
$997.86 Billion | 0.48% | #23 of 34 |
|
IBEX Total Return
IBEXTR
|
$805.53 Billion | 0.59% | #16 of 24 |
|
STOXX Europe Mid 200 EUR Price
MCXP
|
$1.47 Trillion | 0.32% | #69 of 157 |
|
STOXX Europe Mid 200 EUR Net Return
MCXR
|
$1.47 Trillion | 0.32% | #69 of 157 |
Weight: Grifols S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Grifols S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Grifols S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Grifols S.A.'s market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
28.78x
Grifols S.A.'s market cap is 28.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $9.86 Billion | $3.93 Billion | $532.14 Million | 2.51x | 18.52x |
| 2016 | $8.85 Billion | $4.05 Billion | $545.46 Million | 2.19x | 16.22x |
| 2017 | $11.57 Billion | $4.32 Billion | $662.70 Million | 2.68x | 17.46x |
| 2018 | $10.99 Billion | $4.49 Billion | $596.64 Million | 2.45x | 18.41x |
| 2019 | $15.23 Billion | $5.10 Billion | $625.15 Million | 2.99x | 24.36x |
| 2020 | $11.63 Billion | $5.34 Billion | $618.55 Million | 2.18x | 18.81x |
| 2021 | $8.33 Billion | $4.93 Billion | $265.33 Million | 1.69x | 31.40x |
| 2022 | $5.32 Billion | $6.06 Billion | $208.28 Million | 0.88x | 25.53x |
| 2023 | $7.63 Billion | $6.59 Billion | $59.31 Million | 1.16x | 128.64x |
| 2024 | $4.52 Billion | $7.21 Billion | $156.92 Million | 0.63x | 28.78x |
Competitor Companies of GRF by Market Capitalization
Companies near Grifols S.A. in the global market cap rankings as of April 19, 2026.
Key companies related to Grifols S.A. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $317.50 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $829.71 Billion | $927.03 |
| #19 | Johnson & Johnson | NYSE:JNJ | $564.21 Billion | $234.18 |
| #33 | AbbVie Inc | NYSE:ABBV | $368.45 Billion | $208.38 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $317.50 Billion | $204.80 |
Grifols S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Grifols S.A.'s market cap moved from $9.86 Billion to $ 4.76 Billion, with a yearly change of -6.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.76 Billion | -9.85% |
| 2025 | €5.28 Billion | +16.97% |
| 2024 | €4.52 Billion | -40.81% |
| 2023 | €7.63 Billion | +43.50% |
| 2022 | €5.32 Billion | -36.18% |
| 2021 | €8.33 Billion | -28.39% |
| 2020 | €11.63 Billion | -23.62% |
| 2019 | €15.23 Billion | +38.65% |
| 2018 | €10.99 Billion | -5.04% |
| 2017 | €11.57 Billion | +30.73% |
| 2016 | €8.85 Billion | -10.22% |
| 2015 | €9.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Grifols S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.76 Billion USD |
| MoneyControl | $4.76 Billion USD |
| MarketWatch | $4.76 Billion USD |
| marketcap.company | $4.76 Billion USD |
| Reuters | $4.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more